FDA Partially Grants Keryx’s Exclusivity Requests for Auryxia

Drug Industry Daily
A A
While the FDA shot down Keryx Biopharmaceuticals’ request for five-year new chemical entity (NCE) exclusivity for its Auryxia (ferric citrate) oral tablets, it OK’d the drugmaker’s petition for three-year exclusivity.

To View This Article:

Login

Subscribe To Drug Industry Daily